## Shareholder Update: Creative Medical Technology Holdings, Inc. Continues To Extinguish Debt

PHOENIX, April 23, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that additional debt in the amount of \$332,000.00 has been extinguished.

As previously announced Creative Medical Technology Holdings, Inc. took on debt in order to advance our technologies and continue towards our goal of commercialization and cash flow.

"We continue to focus on the business at hand and our portfolio including issued patents for the treatment of erectile dysfunction, degenerative disc disease and our amniotic derived stem cell as well as patents pending in the area of neurological damage due to radiation toxicity and stroke amongst others," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.

As announced on March 26, 2018, we will be exhibiting at the American Urological Association conference in May 2018. We're excited to introduce CaverStem<sup>TM</sup> to a broad base of the urological community.

For those interested in the CaverStem<sup>TM</sup> procedure, please refer to our website at caverstem.com. Only physicians trained and approved for the CaverStem<sup>TM</sup> procedure are identified on our website.

## **About Creative Medical Technology Holdings**

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to <a href="https://www.creativemedicaltechnology.com">www.creativemedicaltechnology.com</a>. For more information on our CaverStem<sup>TM</sup> procedure please go to <a href="https://www.caverstem.com">www.caverstem.com</a>.

## **Forward-Looking Statements**

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

View original content: <a href="http://www.prnewswire.com/news-releases/shareholder-update-creative-medical-technology-holdings-inc-continues-to-extinguish-debt-300634543.html">http://www.prnewswire.com/news-releases/shareholder-update-creative-medical-technology-holdings-inc-continues-to-extinguish-debt-300634543.html</a>

C

SOURCE Creative Medical Technology Holdings, Inc.

For further information: Timothy Warbington, Chief Executive Officer, Tel: (480) 789-9939

https://creativemedicaltechnology.investorroom.com/2018-04-23-Shareholder-Update-Creative-Medical-Technology-Holdings,-Inc-Continues-To-Extinguish-Debt